High-flow nasal oxygen
High-flow nasal oxygen in acute hypoxaemic respiratory failure.
Key point
HFNC is strongly recommended for adults with acute hypoxemic respiratory failure, with close monitoring for escalation, based primarily on reduced need for intubation.
From: Noninvasive respiratory support for adult patients with acute respiratory failure: an official American Thoracic Society Clinical Practice Guideline (Am J Respir Crit Care Med, 2026 Sep 1) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 24, 40, 29, 43, 44.
New guidelines and consensus this year
- Noninvasive respiratory support for adult patients with acute respiratory failure: an official American Thoracic Society Clinical Practice GuidelineAm J Respir Crit Care Med2026 Sep 1
- SEPAR Position Paper on Infrastructure, Technology, Staffing, Quality Standards, and Management of Intermediate Respiratory Care Units in SpainArch Bronconeumol2026 May 23
- SEPAR Position Paper on the Use of High Flow Nasal Cannula Therapy in the Home SettingArch Bronconeumol2026 Jan
All papers from the last 12 months
237 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Commentary on 'The effects of asymmetrical versus symmetrical high-flow nasal cannula on respiratory muscle activity in acute hypoxaemic respiratory failure and chronic obstructive pulmonary disease: A randomised crossover study'Pulmonology2026 DecPMID 42583683
- Assessing respiratory muscle effort during noninvasive respiratory support in acute hypoxemic respiratory failure: A State-of-the Art Review from physiology to bedsideIntensive Crit Care Nurs2026 DecPMID 42407343Review
- The effects of asymmetrical versus symmetrical high-flow nasal cannula on respiratory muscle activity in acute hypoxaemic respiratory failure and chronic obstructive pulmonary disease: A randomised crossover studyPulmonology2026 DecPMID 42345563RCT
- High-Frequency Chest Wall Oscillation in Acute Respiratory Failure With Bronchial Hypersecretion: A Randomized Controlled TrialChest2026 Oct 14PMID 42874912
- Biomarker profiles in COVID-19 and non-covid ARDS: Similar patterns with high-flow nasal cannula and mechanical ventilation, distinct by ARDS etiologyMed Intensiva (Engl Ed)2026 Oct 10PMID 42859118
- Critical care escalation in the peripartum population; a single center retrospective study at an academic quaternary care centerJ Clin Anesth2026 Oct 7PMID 42843214
- Acute Respiratory Failure Survivors' Perspectives on Patient-Centered Communication: A Mixed Methods StudyCrit Care Explor2026 Oct 1PMID 42804356
- High-Flow Nasal Oxygen Versus Conventional Oxygen Therapy and Non-Invasive Ventilation for Acute Respiratory Failure in the Emergency Department: A Systematic Review and Meta-AnalysisEmerg Med Australas2026 OctPMID 42728228Meta-analysisSystematic review
- High-Flow Nasal Cannula Use for Respiratory Support Outside the Paediatric Intensive Care Unit in Children Over 1 Year: A Narrative ReviewJ Paediatr Child Health2026 OctPMID 42698348Review
- Home High-Flow Nasal Cannula Oxygen Therapy in a Chronic Obstructive Pulmonary Disease Patient with Chronic Stable Hypoxemic and Hypercapnic Respiratory FailureTuberc Respir Dis (Seoul)2026 OctPMID 42586530
More pulmonology trends
All specialties →New treatments for sleep apnoea
Tirzepatide, hypoglossal nerve stimulation and drug therapy for obstructive sleep apnoea.
Key point: Pharmacological therapy is not routine OSA treatment; dual GIP/GLP-1 agonists such as tirzepatide may be considered adjunctively for obese moderate-to-severe OSA.
Biologics in COPD
Dupilumab and other biologics for COPD with type 2 inflammation.
Key point: Pooled analyses suggest dupilumab and mepolizumab consistently reduce moderate-to-severe exacerbations in eosinophilic or type 2 inflammatory COPD.
Bronchiectasis
Non-cystic fibrosis bronchiectasis and its newer treatments.
Robotic and navigational bronchoscopy
Robotic and navigation bronchoscopy to biopsy peripheral lung nodules.
Antifibrotics in pulmonary fibrosis
Nintedanib, pirfenidone and newer antifibrotics.
Biologics in severe asthma
Biologic therapies for severe asthma.
Key point: Biologic choice in adult severe asthma can be impacted by quality of life impairment, lung function, exacerbation frequency, oral corticosteroid use, endotype, biomarkers and comorbidities.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("high-flow nasal"[tiab] OR "high flow nasal"[tiab] OR HFNC[tiab]) AND ("respiratory failure"[tiab] OR hypoxemic[tiab] OR hypoxaemic[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.